Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Size: px
Start display at page:

Download "Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)"

Transcription

1 Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for Artery, Atrial Fibrillation, Hypertension and. The PINNACLE Registry metrics are endorsed by the National Quality Forum (), the Physician Consortium for Improvement (PCPI), the Physician Quality Reporting Initiative (PQRI), the American College of Cardiology (ACC), and the American Heart Association (AHA). *Denotes 2010 PQRI s Unique ID PINN-1 Process Artery Metric Type Accrediting Agency ACC/AHA/PCPI ment Name Beta-Blocker Therapy Prior Myocardial Infarction (MI) Description Percentage of CAD patients with prior MI who were prescribed betablocker therapy PINN-2* Artery PQRI (#7) Beta-blocker Therapy for Artery Patients with Prior Myocardial Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease and prior myocardial infarction (MI) who were prescribed beta-blocker therapy PINN-4 Artery Beta-Blocker Therapy-Prior myocardial infarction (MI) Percentage of patients with prior MI at any time who were prescribed beta-blocker therapy PINN-5 Artery Blood Pressure ment Percentage of patients who had a blood pressure measurement during the last office visit 2010 American College of Cardiology Foundation Updated 08/23/10 1

2 PINN-7 Artery Antiplatelet Therapy Percentage of patients who were prescribed antiplatelet therapy PINN-8* Artery PQRI (#6) Oral Antiplatelet Therapy Prescribed for Patients with Artery Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease who were prescribed oral antiplatelet therapy PINN-10 Artery CAD: Antiplatelet Therapy Percentage of patients with CAD who were prescribed antiplatelet therapy PINN-11 Artery Screening for Diabetes Percentage of patients who were screened for diabetes PINN-13* All Patie nts PQRI (#47) Advance Care Plan Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan in the medical record PINN-14 Artery Advance Care Plan Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan PINN-15 Artery Smoking Cessation Percentage of patients who were queried one or more times about cigarette smoking PINN-18 Artery Tobacco use prevention for infants, children, and adolescents PINN-19 Artery Smoking Cessation Percentage of patients identified as cigarette smokers who received smoking cessation intervention 2010 American College of Cardiology Foundation Updated 08/23/10 2

3 PINN-20* ALL PQRI (#115) Advising Smokers and Tobacco Users to Quit Percentage of patients aged 18 years and older and are smokers or tobacco users who received advice to quit smoking PINN-22 Artery Tobacco Cessation Intervention Percentage of patients identified as tobacco users who received cessation intervention during the two-year measurement period PINN-24 Artery Cardiac Rehabilitation Patient Referral From an Outpatient Setting All patients evaluated in an outpatient setting who within the past 12 months have experienced an acute myocardial infarction (MI), coronary artery bypass graft (CABG) surgery, a percutaneous coronary intervention (PCI), cardiac valve surgery, or cardiac transplantation, or who have chronic stable angina (CSA) and have not already participated in an early outpatient cardiac rehabilitation/secondary prevention (CR) program for the qualifying event/diagnosis are to be referred to such a program. PINN-25 Artery Symptom & Activity Assessment Percentage of patients who were evaluated for both level of activity and anginal symptoms during one or more office visits PINN-27 Artery Artery (CAD): Symptom and Activity Assessment Percentage of patients with CAD who were evaluated for both level of activity and anginal symptoms during one or more office visits PINN-29 Artery ACE Inhibitor or ARB Therapy Percentage of CAD patients who also have diabetes and/or LVSD who were prescribed ACE inhibitor or ARB therapy PINN-30* Artery PQRI (#118) Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) Percentage of patients aged 18 years and older with a diagnosis of CAD who also have diabetes mellitus and/or LVSD (LVEF < 40%) who were prescribed ACE inhibitor or ARB therapy 2010 American College of Cardiology Foundation Updated 08/23/10 3

4 PINN-32 Artery CAD: ACE inhibitor/angiotensin receptor blocker (ARB) Therapy Percentage of patients with CAD who also have diabetes and/or LSVD who were prescribed ACE inhibitor or ARB therapy. PINN-33 Artery Lipid Profile Percentage of patients who received at least one lipid profile (or ALL component tests) PINN-35 Artery Drug Therapy for Lowering LDL- Cholesterol Percentage of patients who were prescribed lipid-lowering therapy (based on current ACC/AHA guidelines) PINN-37 Artery Drug Therapy for Lowering LDL- Cholesterol Percentage of patients with CAD who were prescribed a lipid lowering therapy (based on current ACC/AHA guidelines) PINN-38 Left Ventricular Systolic (LVS) Function Assessment Heart failure patients with documentation that LVS function has been assessed PINN-40 Left Ventricular Function (LVF) assessment Percentage of patients with HF with quantitative or qualitative results of left ventricular function (LVF) assessment recorded PINN-41 Weight ment ment of patient s weight at each outpatient visit to assess change in volume status PINN-43 H eart Failure Weight ment Percentage of patient visits for patients with HF with weight measurement recorded PINN-44 Blood Pressure ment ment of patient s blood pressure at each outpatient visit 2010 American College of Cardiology Foundation Updated 08/23/10 4

5 PINN-46 Patient Education Percentage of patients who were provided with patient education on disease management and health behavior changes during one or more visits within the period of assessment PINN-48 Percentage of patients who were provided with patient education on disease management and health behavior changes during one or more visit(s) PINN-49 ACE Inhibitor or Angiotensin Receptor Blocker (ARB) for Patients with Heart Failure Who Have Left Ventricular Systolic Dysfunction (LVSD) Prescription of ACE inhibitor or ARB for management of outpatient HF patients with LVSD PINN-50* PQRI (#5) Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) Percentage of patients aged 18 years and older with a diagnosis of heart failure and left ventricular systolic dysfunction (LVSD) who were prescribed ACE inhibitor or ARB therapy PINN-52 ACEI/ ARB Therapy Percentage of patients with HF who also have left ventricular systolic dysfunction (LVSD) who were prescribed ACE inhibitor or ARB therapy. PINN-53 Warfarin Therapy for Patients with Atrial Fibrillation (AF) Use of warfarin in patients with both HF and AF 2010 American College of Cardiology Foundation Updated 08/23/10 5

6 PINN-54 Afib/Flutter Chronic Anticoagulation Therapy Prescription of warfarin for all patients with nonvalvular AF or atrial flutter at high risk for thromboembolism, according to risk stratification and 2006 guideline recommendations, as follows: Low risk No risk factors Aspirin 81 to 325 mg daily Intermediate risk One moderate-risk factor Aspirin 81 to 325 mg daily or warfarin (INR 2.0 to 3.0, target 2.5) High risk Any high-risk factor or more than 1 moderate-risk factor Warfarin (INR 2.0 to 3.0, target 2.5) PINN-57 Warfarin Therapy Patients with Atrial Fibrillation Percentage of patients with HF who also have paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy PINN-58 Assessment of Activity Level Evaluation of the impact of HF on activity level at each outpatient visit (standardized scale or assessment tool may be used) PINN-60 Assessment of Activity Level Percentage of patient visits or patients with HF with assessment of activity level. PINN-61 Assessment of Clinical Signs of Volume Overload (Excess) Completion of a physical examination pertaining to volume status assessment in patients diagnosed with HF at each outpatient visit (standardized scale or assessment tool may be used) PINN-63 Assessment of clinical symptoms of volume overload (Excess) Percentage of patient visits or patients with HF with assessment of clinical symptoms of volume overload (excess) PINN-64 Initial Laboratory Tests Initial laboratory evaluation of patients with newly diagnosed HF PINN-66 Afib/Flutter Assessment of Thromboembolic Risk Factors Patients with nonvalvular AF or atrial flutter in whom assessment of thromboembolic risk factors has been documented 2010 American College of Cardiology Foundation Updated 08/23/10 6

7 PINN-68 Assessment of Clinical Symptoms of Volume Overload (Excess) Assessment of patient s clinical symptoms of volume overload at each outpatient visit (standardized scale or assessment tool may be used) PINN-72 Hypertension Blood Pressure ment Percentage of patient visits with blood pressure measurement recorded PINN-74 Hypertension Blood Pressure ment Percentage of patient visits with blood pressure measurement recorded among all patient visits for patients aged > 18 years with diagnosed hypertension PINN-75 Hypertension Plan of Care Percentage of patient visits with either systolic blood pressure 140 mm Hg or diastolic blood pressure 90 mm Hg, with documented plan of care for hypertension PINN-77 Hypertension Plan of Care Percentage of patient visits during which either systolic blood pressure > 140 mm Hg or diastolic blood pressure > 90 mm Hg, with documented plan of care for hypertension PINN-78 Beta-Blocker Therapy Prescription of beta-blockers in patients with HF and left ventricular systolic dysfunction (LVSD) PINN-79* PQRI (#8) Beta-blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) Percentage of patients aged 18 years and older with a diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were prescribed beta blocker therapy PINN-81 Beta-blocker therapy Percentage of patients with HF who also have LVSD who were prescribed beta-blocker therapy PINN-82* ALL PQRI (#114) Preventive Care and Screening: Inquiry Regarding Tobacco Use Percentage of patients aged 18 years or older who were queried about tobacco use one or more times within 24 months 2010 American College of Cardiology Foundation Updated 08/23/10 7

8 PINN-83* ALL PQRI (#124) Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR) Documents whether provider has adopted and is using health information technology. To qualify, the provider must have adopted and be using a certified/qualified EHR PINN-84* Artery PQRI (#196) Artery (CAD): Symptom and Activity Assessment Percentage of patients aged 18 years and older with a diagnosis of CAD who were evaluated for both level of activity and anginal symptoms during one or more visits PINN-85* Artery PQRI (#197) Artery (CAD): Drug Therapy for Lowering LDL-Cholesterol Percentage of patients aged 18 years and older with a diagnosis of CAD who were prescribed a lipid-lowering therapy (based on current ACC/AHA guidelines) PINN-86* PQRI (#198) : Left Ventricular Function (LVF) Assessment Percentage of patients aged 18 years and older with a diagnosis of heart failure who have quantitative or qualitative results of LVF assessment recorded PINN-87* PQRI (#199) : Patient Education Percentage of patients aged 18 years and older with a diagnosis of heart failure who were provided with patient education on disease management and health behavior changes during one or more visit(s) within 12 months PINN-88* PQRI (#200) : Warfarin Therapy for Patients with Atrial Fibrillation Percentage of all patients aged 18 and older with a diagnosis of heart failure and paroxysmal or chronic atrial fibrillation who were prescribed warfarin therapy PINN-89 Artery Guideline Recommendation Antiplatelet Use (Excluding ASA) after Stent Placement The percentage of CAD patients that receive an antiplatelet (excluding Aspirin) after a Drug Eluting Stent or Bare Metal Stent placement within the past year American College of Cardiology Foundation Updated 08/23/10 8

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.

More information

Practice-Level Executive Summary Report

Practice-Level Executive Summary Report PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular

More information

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer

More information

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for

More information

Quality Payment Program: Cardiology Specialty Measure Set

Quality Payment Program: Cardiology Specialty Measure Set Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor

More information

2016 Internal Medicine Preferred Specialty Measure Set

2016 Internal Medicine Preferred Specialty Measure Set 1 0059 Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%): Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period 5 0081 Registry, EHR, 9 0105

More information

2016 General Practice/Family Practice Preferred Specialty Measure Set

2016 General Practice/Family Practice Preferred Specialty Measure Set 1 0059 5 0081 41 N/A 50 N/A 65 0069, EHR 66 0002, EHR Effective Clinical Care Effective Clinical Care Effective Clinical Care Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%): Percentage of patients

More information

Consensus Core Set: Cardiovascular Measures Version 1.0

Consensus Core Set: Cardiovascular Measures Version 1.0 Consensus Core Set: Cardiovascular s NQF 0330 Hospital 30-day, all-cause, riskstandardized readmission rate (RSRR) following heart failure hospitalization 0229 Hospital 30-day, all-cause, riskstandardized

More information

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings

Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings CMS-1345-P 174 Table 1. Proposed Measures for Use in Establishing Quality Performance Standards that ACOs Must Meet for Shared Savings AIM: Better Care for Individuals 1. Patient/Care Giver Experience

More information

Meaningful Use Clinical Quality Measures for Eligible Professionals

Meaningful Use Clinical Quality Measures for Eligible Professionals Meaningful Use Clinical Quality Measures for Eligible Professionals Measure Type NQF ID CMS ID Description Title: Adult Weight Screening and Follow-Up 1 NQF 0421 PQRI 128 calculated BMI in the past six

More information

NQF Measure Number & PQRI Implementation Number

NQF Measure Number & PQRI Implementation Number Title NQF Steward s Adult Weight Screening and Follow-Up Hypertension: Blood Pressure ment Preventive Care and Screening Pair: a. Tobacco Use Assessment, b. Tobacco Cessation Intervention with a calculated

More information

Clinical Quality Measures for Submission by Medicare or Medicaid EP/s for the 2011 and 2012 Payment Year

Clinical Quality Measures for Submission by Medicare or Medicaid EP/s for the 2011 and 2012 Payment Year 1 NQF 0059 1 NQF 0064 2 NQF 0061 3 Title: Diabetes: Hemoglobin A1c Poor Control Description: Percentage of patients 18-75 years of age with diabetes (type 1 or type 2) who had hemoglobin A1c > 9.0%. Title:

More information

Clinical Quality Measures

Clinical Quality Measures Core Measures Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment, b. Tobacco Cessation Intervention. Percentage of patients aged 18 years and older who have been seen for at least 2

More information

Quality Measures MIPS CV Specific

Quality Measures MIPS CV Specific Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from

More information

For Electronic Measure Specification Information go to:

For Electronic Measure Specification Information go to: Diabetes Recognition NQF 0421 PQRI 128 Title: Adult Weight Screening and Follow-Up Description: Percentage of patients aged 18 years and older with a calculated BMI in the past six months or during the

More information

CLINICAL QUALITY MEASURES Stage 1 Meaningful Use

CLINICAL QUALITY MEASURES Stage 1 Meaningful Use CLINICAL QUALITY MEASURES Stage 1 Meaningful Use * Eligible professionals (EPs) must report on 3 required core clinical quality measures (CQMs). If the denominator of 1 or more of the required core measures

More information

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to

More information

HF QUALITY MEASURES. Hydralazine/nitrate at discharge: Percent of black heart

HF QUALITY MEASURES. Hydralazine/nitrate at discharge: Percent of black heart Get With The Guidelines - Heart Failure is the American Heart Association s collaborative quality improvement program, demonstrated to improve adherence to evidence-based care of patients hospitalized

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Clinical Practice Guideline

Clinical Practice Guideline Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)

More information

Meaningful Use Criteria for Pediatric Providers

Meaningful Use Criteria for Pediatric Providers SET OF CRITERIA - 15 REQUIRED These 15 core criteria are called the core set and are required elements for demonstrating meaningful use. This document was prepared for pediatric providers so language pertaining

More information

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium Know the Quality of our Care at Every Step Kansas City ACS Summit BI-State Cardiovascular Education Consortium Welcome to the Kansas City ACS Summit Objectives: Follow the flow and care of an ACS patient

More information

Coronary Artery Disease Clinical Practice Guidelines

Coronary Artery Disease Clinical Practice Guidelines Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.

More information

Meaningful Use for Eligible Providers

Meaningful Use for Eligible Providers Meaningful Use for Eligible Providers Summary of Core and Menu objectives and Clinical Quality s Healthcare Technical Assistance Program, March 11, 2011 V.1.0Copyright 2011, Purdue Research Foundation

More information

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner

Measure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner 2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current

More information

proposed set to a required subset of 3 to 5 measures based on the availability of electronic

proposed set to a required subset of 3 to 5 measures based on the availability of electronic CMS-0033-P 143 proposed set to a required subset of 3 to 5 measures based on the availability of electronic measure specifications and comments received. We propose to require for 2011 and 2012 that EP's

More information

2012 Core Measures. Acute Myocardial Infarction (AMI)

2012 Core Measures. Acute Myocardial Infarction (AMI) 2012 Core Measures Acute Myocardial Infarction (AMI) Aspirin at Arrival Aspirin Prescribed at Discharge Angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) for left ventricular

More information

4. Which survey program does your facility use to get your program designated by the state?

4. Which survey program does your facility use to get your program designated by the state? STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI

More information

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW

CORONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW CONARY ARTERY DISEASE (CAD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN CONARY ARTERY DISEASE (CAD) MEASURES GROUP: #6. Coronary Artery Disease (CAD): Antiplatelet

More information

THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40%

THERE ARE TWO SUBMISSION CRITERIA FOR THIS MEASURE: 1) Patients who are 18 years and older with a diagnosis of CAD with LVEF < 40% Quality ID #118 (NQF 0066): Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction

More information

The Future of Cardiac Care: Managing Our Patients Together

The Future of Cardiac Care: Managing Our Patients Together The Future of Cardiac Care: Managing Our Patients Together Charles R. Caldwell, MD, FACC Disclosures: iheartdoc,inc. Telemedicine 1 MACRA Medicare Access and CHIP Reauthorization Act of 2015 Repealed the

More information

Measure Owner Designation. AMA-PCPI/NCQA (contract) is the measure owner. AMA-PCPI is the measure owner. AMA-PCPI/ASCO/NCCN is the measure owner

Measure Owner Designation. AMA-PCPI/NCQA (contract) is the measure owner. AMA-PCPI is the measure owner. AMA-PCPI/ASCO/NCCN is the measure owner 2012 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current

More information

HEART FAILURE QUALITY IMPROVEMENT. American Heart Association Shawni Smith Regional Director, Quality & Systems Improvement

HEART FAILURE QUALITY IMPROVEMENT. American Heart Association Shawni Smith Regional Director, Quality & Systems Improvement HEART FAILURE QUALITY IMPROVEMENT American Heart Association Shawni Smith Regional Director, Quality & Systems Improvement 1 DISCLOSURES NONE 2 3 WHY IS THIS IMPORTANT? WHY? Heart Failure Currently, an

More information

2018 MIPS Reporting Family Medicine

2018 MIPS Reporting Family Medicine 2018 MIPS Reporting Family Medicine Quality Reporting Requirements: Report on 6 quality measures or a specialty measure set Include at least ONE outcome or high-priority measure Report on patients of All-Payers

More information

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: MacLean CH, Kerr EA, Qaseem A. Time out charting a path for

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

2016 Physician Quality Reporting System (PQRS) GPRO Web Interface Measures List 12/18/2015

2016 Physician Quality Reporting System (PQRS) GPRO Web Interface Measures List 12/18/2015 2016 Physician Quality Reporting System (PQRS) Web Interface 12/18/2015 NQF, ) Care Coordination/Patient Safety (CARE) s (2 s Individually Sampled) CARE-2 Falls: Screening for Future Fall Risk Only #318

More information

Improving Quality of Care for Medicare Patients: Accountable Care Organizations

Improving Quality of Care for Medicare Patients: Accountable Care Organizations DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Room 352-G 200 Independence Avenue, SW Washington, DC 20201 Office of Media Affairs MEDICARE FACT SHEET FOR IMMEDIATE RELEASE

More information

Cardiac Performance Measure Compliance in Outpatients

Cardiac Performance Measure Compliance in Outpatients Journal of the American College of Cardiology Vol. 56, No. 1, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.03.043

More information

MACRA Quality Payment Program Guide. Sample page. Simplifying Medicare MIPS & APM reporting for practitioners. Power up your coding optum360coding.

MACRA Quality Payment Program Guide. Sample page. Simplifying Medicare MIPS & APM reporting for practitioners. Power up your coding optum360coding. 2019 MACRA Quality Payment Program Guide Simplifying Medicare MIPS & APM reporting for practitioners Power up your coding optum360coding.com Contents Chapter 1. MACRA and the Quality Payment Program...

More information

The CSAC will review recommendations from the Cardiovascular 2015 project during its January 12, 2016 conference call.

The CSAC will review recommendations from the Cardiovascular 2015 project during its January 12, 2016 conference call. TO: FR: RE: Consensus Standards Approval Committee (CSAC) Melissa Marinelarena, Leslie Vicale, Donna Herring Cardiovascular 2015 Member Voting Results DA: January 12, 2016 The CSAC will review recommendations

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective

More information

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease

More information

NATIONAL QUALITY FORUM

NATIONAL QUALITY FORUM Cardiovascular and Diabetes Task Force Summary of In-Person Meeting #2 An in-person meeting of the Measure Applications Partnership (MAP) Cardiovascular and Diabetes Task Force was held on Tuesday, July

More information

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

The Role of Health Information Technology in Implementing Disease Management Programs

The Role of Health Information Technology in Implementing Disease Management Programs The Role of Health Information Technology in Implementing Disease Management Programs Donald F. Wilson, MD Medical Director Quality Insights of Pennsylvania May 11, 2006 Statewide Combined Topic Average

More information

Comprehensive ESRD Care (CEC) Model Proposed Quality Measures for Public Comment. Table of Contents

Comprehensive ESRD Care (CEC) Model Proposed Quality Measures for Public Comment. Table of Contents Comprehensive ESRD Care (CEC) Model Proposed Quality s for Public Comment Table of Contents Page # Introduction 3 Summaries by Domain Technical Expert Panel Recommended CEC Quality s 4 s that were recommended

More information

Certified Health IT Transparency and Disclosure Information 2014 Edition

Certified Health IT Transparency and Disclosure Information 2014 Edition Certified Health IT Transparency and Disclosure Information 2014 Edition 2015 Edition Certified Health IT Transparency and Disclosure Information I. Disclaimer This Complete EHR is 2014 Edition compliant

More information

Do Not Cite. Draft for Work Group Review.

Do Not Cite. Draft for Work Group Review. Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted

More information

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland Conflict of Interests No conflict

More information

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근

Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)

More information

Toledo Hospital Clinical Quality Indicators. Effective - Heart Attack

Toledo Hospital Clinical Quality Indicators. Effective - Heart Attack Effective - Heart Attack This page shows information on effective measures for patients who had heart attacks. "Effective care" means patients are given treatments that scientific evidence has shown leads

More information

Chapter 4: Cardiovascular Disease in Patients with CKD

Chapter 4: Cardiovascular Disease in Patients with CKD Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%

More information

OCHSNER PHYSICIAN PARTNERS. PQRS Measures by Specialty (FINAL)

OCHSNER PHYSICIAN PARTNERS. PQRS Measures by Specialty (FINAL) OCHSNER PHYSICIAN PARTNERS PQRS Measures by Specialty (FINAL) Allergy and Immunology 2. Asthma: Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting (PQRS 53) 3. Patients aged 18 years

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1

More information

Coronary Heart Disease

Coronary Heart Disease Coronary Heart Disease This document is a final specification of the PRIMIS Comparative Analysis Service (CAS) MIQUEST query set to enable analyses in support of the NSF for CHD. The specification has

More information

Meaningful Use Simple Guide

Meaningful Use Simple Guide Meaningful Use Simple Guide 2011-2012 CORE Measures 1. CPOE for Medication Orders 2. Drug Interaction Checks * 3. Maintain Problem & Diagnosis List 4. eprescribing (erx) escripts 5. Active Medication List

More information

2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Disease (CAD) (for patients aged 18 and older)

2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Disease (CAD) (for patients aged 18 and older) 2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Disease (CAD) (for patients aged 18 and older) IMPORTANT: Any measure with a 0% performance rate (100% for inverse measures)

More information

APPENDIX F: CASE REPORT FORM

APPENDIX F: CASE REPORT FORM APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more

More information

2) Patients who are 18 years and older with a diagnosis of CAD or history of cardiac surgery who have a prior myocardial infarction

2) Patients who are 18 years and older with a diagnosis of CAD or history of cardiac surgery who have a prior myocardial infarction Measure #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) National Quality Strategy Domain: Effective

More information

Perioperative Management. Perioperative Management of Cardiovascular Medications

Perioperative Management. Perioperative Management of Cardiovascular Medications of Cardiovascular Medications Carmine D Amico, D.O. Overview Learning objectives Beta-blockers Statins Alpha-2 agonists Calcium channel blockers ACE inhibitors and ARB s Anticoagulants Antiplatelet agents

More information

Chapter 8: Cardiovascular Disease in Patients with ESRD

Chapter 8: Cardiovascular Disease in Patients with ESRD Chapter 8: Cardiovascular Disease in Patients with ESRD Cardiovascular disease (CVD) is common in adult end-stage renal disease (ESRD) patients, with coronary artery disease (CAD) and heart failure (HF)

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

Acute Coronary Syndrome (ACS) Initial Evaluation and Management

Acute Coronary Syndrome (ACS) Initial Evaluation and Management Acute Coronary Syndrome (ACS) Initial Evaluation and Management Symptoms of Possible ACS Chest discomfort with or without radiation to the arm(s), jaw, or epigastrium Short of breath Weakness Diaphoresis

More information

Meaningful Use Overview

Meaningful Use Overview Eligibility Providers may be eligible for incentives from either Medicare or Medicaid, but not both. In addition, providers may not be hospital based. Medicare: A Medicare Eligible Professional (EP) is

More information

ACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter

ACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter ACC/AHA/Physician Consortium Clinical Performance Measures for Adults with Nonvalvular Atria Fibrillation or Atrial Flutter A Report of the American College of Cardiology/American Heart Association Task

More information

Group Practice Reporting Option I (GPRO I)

Group Practice Reporting Option I (GPRO I) 2011 Physician Quality Reporting System (Physician Quality Reporting) Previously known as Physician Quality Reporting Initiative (PQRI) Group Practice Reporting Option I (GPRO I) Narrative Measure Specifications

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic

More information

2010 Physician Quality Reporting Initiative Measures Groups Specifications Manual

2010 Physician Quality Reporting Initiative Measures Groups Specifications Manual 2010 Physician Quality Reporting Initiative Measures Groups Specifications Manual This manual contains specific guidance for reporting 2010 Physician Quality Reporting Initiative (PQRI) Measures Groups.

More information

GET WITH THE GUIDELINES- PAST AND FUTURE

GET WITH THE GUIDELINES- PAST AND FUTURE GET WITH THE GUIDELINES- PAST AND FUTURE Amy Graham, RN, BS, CEN, NREMT-P Director, Quality & Systems Improvement Kentucky and Southwest Ohio American Heart Association 1 DISCLOSURE SLIDE I AM THE QUALITY

More information

3309 Risk-Standardized Survival Rate (RSSR) for In-Hospital Cardiac Arrest (American Heart Association)

3309 Risk-Standardized Survival Rate (RSSR) for In-Hospital Cardiac Arrest (American Heart Association) Memo March 8, 2018 To: NQF Members and the Public From: NQF Staff Re: Commenting Draft Report: National Voluntary Consensus Standards for Cardiovascular Background This report reflects the review of measures

More information

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):

More information

CVD Outcomes Aggregate Report Report Period: 05/01/ /30/2004

CVD Outcomes Aggregate Report Report Period: 05/01/ /30/2004 Changes in JNC VII Blood Pressure Categories Blood Pressure Category Initial Value ¹ Latest Value ¹ Improvement ² (Based on JNC VII Guidelines) values (days) (N=271) (N = 209) Normal (SBP < 120 and DBP

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total

More information

Controversies in Cardiac Pharmacology

Controversies in Cardiac Pharmacology Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?

More information

2014 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

2014 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY Measure #7 (NQF 0070): Coronary Artery Disease (CAD): Beta-Blocker Therapy Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) 2014 PQRS OPTIONS F INDIVIDUAL MEASURES:

More information

Writing Committee. ACP Performance Measurement Committee Members*

Writing Committee. ACP Performance Measurement Committee Members* Performance Measurement Management of Coronary Artery Disease: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians Writing Committee Amir Qaseem,

More information

2015 Healthy Heart. Program Evaluation. Our mission is to improve the health and quality of life of our members

2015 Healthy Heart. Program Evaluation. Our mission is to improve the health and quality of life of our members 2015 Healthy Heart Program Evaluation Our mission is to improve the health and quality of life of our members 2015 Healthy Heart Program Evaluation Program Title: Healthy Heart Program Evaluation Period:

More information

Acute Myocardial Infarction

Acute Myocardial Infarction Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:

More information

1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued,

1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued, Experts Answering Your Questions Anticoagulating a high-risk cardiac patient 1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy for minor surgical

More information

Cardiovascular Conditions

Cardiovascular Conditions Cardiovascular Conditions 2016-2017 TECHNICAL REPORT February 23, 2017 This report is funded by the Department of Health and Human Services under contract HHSM-500-2012-00009I Task Order HHSM-500-T0008.

More information

Reliability of the incremental shuttle walk test and the Chester step test in cardiac rehabilitation

Reliability of the incremental shuttle walk test and the Chester step test in cardiac rehabilitation Reliability of the incremental shuttle walk test and the Chester step test in cardiac rehabilitation Item Type Thesis or dissertation Authors Reardon, Melanie Publisher University of Chester Download date

More information

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0

Consensus Core Set: ACO and PCMH / Primary Care Measures Version 1.0 Consensus Core Set: ACO and PCMH / Primary Care s 0018 Controlling High Blood Pressure patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately

More information

convey the clinical quality measure's title, number, owner/developer and contact

convey the clinical quality measure's title, number, owner/developer and contact CMS-0033-P 153 convey the clinical quality measure's title, number, owner/developer and contact information, and a link to existing electronic specifications where applicable. TABLE 20: Proposed Clinical

More information

The Role of Cardiac Rehabilitation in Recovery & Secondary Prevention. Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager

The Role of Cardiac Rehabilitation in Recovery & Secondary Prevention. Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager The Role of Cardiac Rehabilitation in Recovery & Secondary Prevention Loren M Stabile, MS Cardiac & Pulmonary Rehab Program Manager Objectives Core Components of Cardiac Rehab Program CR Indications &

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of

More information

Intervention Recommendations with Class of Recommendation and Level of Evidence

Intervention Recommendations with Class of Recommendation and Level of Evidence Intervention Recommendations with Class of Recommendation and Level of Evidence RISK: BLOOD PRESSURE CONTROL: LIPID Goal: to identify people who will benefit from risk reduction strategies Goal:

More information

VHA Performance Measurement In Cardiac Care

VHA Performance Measurement In Cardiac Care VHA Performance Measurement In Cardiac Care A Map for VHA Cardiac Performance Measurement in FY 2005 and beyond Roxane Rusch, BSN, MPA, RN Department Of Veterans Affairs Office of Quality and Performance

More information

was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr..

was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr.. Patient: was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr.. Discharge Diagnoses include: q CAD-CCS Class: m 0 m 1 m 2 m 3 m 4 q Unstable angina q Non STEMI (non-st

More information

Supplementary Material to Mayer et al. A comparative cohort study on personalised

Supplementary Material to Mayer et al. A comparative cohort study on personalised Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass

More information

Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists

Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists Overview of Current Quality Measures that can be Impacted by Ambulatory Pharmacists Measure Name Measure Domain Measure Focus Comment/Explanation CMS Value-based Purchasing Program (CMS VBP) AMI 30-day

More information

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017 GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional

More information

Heart Failure Clinician Guide JANUARY 2016

Heart Failure Clinician Guide JANUARY 2016 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.

More information

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

Acute Myocardial Infarction. Willis E. Godin D.O., FACC Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable

More information